Elastic tape as an add-on strategy to potentiate pulmonary rehabilitation outcomes in nonobese males with moderate-to-very severe COPD: A randomised clinical trial.

Pulmonology 2026-08-19Keyword sweep match

de Melo Batista Dos Santos J, Pinto TF, Reis ECM, Marques da Silva CCB, Carvalho-Pinto RM, de Lima FF, Carvalho CRF

Abstract

Background and objective Pulmonary rehabilitation (PR) improves exercise capacity but has limited effects on ventilatory constraints in severe COPD. Application of elastic tape (ET) is a potential adjunctive strategy that improves ventilatory efficiency, but its effects during PR remain un lear. This study investigated whether ET potentiates PR benefits on exercise capacity, health status, psychological symptoms, and health-related quality of life (HRQoL) in individuals with COPD. Methods Forty-two nonobese men with moderate-to-very severe COPD were randomised to ET or Sham groups during an 8-week PR programme. The primary outcome was endurance shuttle walk test (ESWT) time; secondary outcomes included COPD Assessment Test (CAT), Chronic Respiratory Questionnaire (CRQ), and Hospital Anxiety and Depression Scale (HADS). Results ESWT improved by +329s in the ET group, exceeding the MCID. Greater CAT improvements ( p = 0.02), and a higher proportion achieving minimal clinically important difference (MCID) (48% vs. 29%; p = 0.02) were observed in the ET group. Only ET group achieved MCIDs for depression ( p = 0.003) and anxiety ( p = 0.02). HRQoL improved similarly in both groups. The only outcome with a significant time × group interaction was HADS-D ( p = 0.001), improved by ET. Only This study was performed in accordance with the Declaration of Helsinki. This human study was approved by Ethics Committee for Analysis of Research Projects (CAPPesq) of School of Medicine of the University of São Paulo - Hospital das Clínicas (approval 55 617 321.20000.0068). All adult participants provided written informed consent to participate in this study. Clinical Trial Registration number NCT05939999 (https://clinicaltrials.gov), registered on October 26 th , 2025.ET group presented moderate-to-large effect sizes for ESWT (d = 0.89), HADS-A (d = 0.51) and HADS-D (d = 1.02). Conclusions ET potentiates PR benefits on exercise capacity, health status, and psychological symptoms in individuals with moderate-to-very severe COPD.

MeSH terms: Humans, Pulmonary Disease, Chronic Obstructive, Treatment Outcome, Severity of Illness Index, Depression, Anxiety, Health Status, Exercise Tolerance, Quality of Life, Aged, Middle Aged, Male, Surveys and Questionnaires, Walk Test